B-910, 401, Yangcheon-ro
82 2 322 1687
Full Time Employees: 76
|Mr. Won-Il Yoo||Chief Exec. Officer and Pres||N/A||N/A||N/A|
|Dr. Yang-Je Cho||Co-Founder and Chief Technology Officer||N/A||N/A||N/A|
|Soobeom Lee||Chief Financial Officer||N/A||N/A||N/A|
EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, a Phase IIa clinical trial product candidate for the treatment of diabetic retinopathy; EG-Decorin, a Phase I/II clinical trial product for the treatment for pressure ulcers; EG-Myocin, a product that is in Phase II clinical trials for the treatment of heart muscle; and EG-HPV, a product that completed Phase I clinical trial for the treatment of cervical cancer. Its products in pipeline also include EG-TB for the treatment of tuberculosis; and EG-HZ, which is in preclinical trials for the treatment of herpes zoster. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
EyeGene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.